Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) – Pipeline Review, H2 2017’, provides in depth analysis on Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Ophthalmology under development targeting Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects

The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

CASI Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Ildong Pharmaceutical Co Ltd

NewLink Genetics Corp

OncoImmune Inc

Peloton Therapeutics Inc

RXi Pharmaceuticals Corp

Sorrento Therapeutics Inc

Vascular Biogenics Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Overview 7

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development 24

CASI Pharmaceuticals Inc 24

Daiichi Sankyo Co Ltd 24

Ildong Pharmaceutical Co Ltd 25

NewLink Genetics Corp 25

OncoImmune Inc 26

Peloton Therapeutics Inc 26

RXi Pharmaceuticals Corp 27

Sorrento Therapeutics Inc 27

Vascular Biogenics Ltd 28

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles 29

A-503451A - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BC-001 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CASI-2ME2 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CRLX-101 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Echinomycin - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

HS-1793 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

IDF-11774 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

KCN-1 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

MPT-0B098 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Inhibit HIF-1 Alpha for Oncology - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

SR-16388 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

TR-764 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VB-411 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Products 59

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products 62

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Product Development Milestones 63

Featured News & Press Releases 63

Oct 06, 2016: Cerulean Announces Clinical Data from CRLX101 Program at the 2016 European Society for Medical Oncology Annual Meeting 63

Aug 18, 2016: Cerulean Announces Reduction in Force 64

Aug 18, 2016: Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma 64

Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer 65

Jun 22, 2016: Cerulean Announces Publication in Cancer Research 65

Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology 66

May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference 66

May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA 67

Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference 68

Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer 68

Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue 70

Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting 71

Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 73

Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 74

Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101 75

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 23

Pipeline by CASI Pharmaceuticals Inc, H2 2017 24

Pipeline by Daiichi Sankyo Co Ltd, H2 2017 25

Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017 25

Pipeline by NewLink Genetics Corp, H2 2017 26

Pipeline by OncoImmune Inc, H2 2017 26

Pipeline by Peloton Therapeutics Inc, H2 2017 27

Pipeline by RXi Pharmaceuticals Corp, H2 2017 27

Pipeline by Sorrento Therapeutics Inc, H2 2017 28

Pipeline by Vascular Biogenics Ltd, H2 2017 28

Dormant Products, H2 2017 59

Dormant Products, H2 2017 (Contd..1), H2 2017 60

Dormant Products, H2 2017 (Contd..2), H2 2017 61

Discontinued Products, H2 2017 62

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Molecule Types, H2 2017 22

Number of Products by Stage and Molecule Types, H2 2017 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports